Heregulin drives endocrine resistance by altering il-8 expression in er-positive breast cancer

ATLAS, ELLA; VERDURA, SARA; LUPU, RUTH; PAPADIMITROPOULOU, ADRIANA; STEEN, TRAVIS VANDER; ESPINOZA, INGRID; VELLON, LUCIANO; CUYÀS, ELISABET; MENENDEZ, JAVIER A.

International Journal of Molecular Sciences

MDPI AG

Año: 2020 vol. 21 p. 1 - 15

1661-6596

Sustained HER2/HER3 signaling due to the overproduction of the HER3 ligand heregulin (HRG) is proposed as a key contributor to endocrine resistance in estrogen receptor-positive (ER+) breast cancer. The molecular mechanisms linking HER2 transactivation by HRG-bound HER3 to the acquisition of a hormone-independent phenotype in ER+ breast cancer is, however, largely unknown. Here, we explored the possibility that autocrine HRG signaling drives cytokine-related endocrine resistance in ER+ breast cancer cells. We used human cytokine antibody arrays to semi-quantitatively measure the expression level of 60 cytokines and growth factors in the extracellular milieu of MCF-7 cells engineered to overexpress full-length HRGβ2 (MCF-7/HRG cells). Interleukin-8 (IL-8), a chemokine closely linked to ER inaction, emerged as one the most differentially expressed cytokines. Cytokine profiling using structural deletion mutants lacking both the N-terminus and the cytoplasmic-transmembrane region of HRGβ2?which is not secreted and cannot transactivate HER2?or lacking a nuclear localization signal at the N-terminus?which cannot localize at the nucleus but is actively secreted and transactivates HER2?revealed that the HRG-driven activation of IL-8 expression in ER+ cells required HRG secretion and transactivation of HER2 but not HRG nuclear localization. The functional blockade of IL-8 with a specific antibody inversely regulated ERα-driven transcriptional activation in endocrine-sensitive MCF-7 cells and endocrine-resistant MCF-7/HRG cells. Overall, these findings suggest that IL-8 participates in the HRG-driven endocrine resistance program in ER+/HER2-breast cancer and might illuminate a potential clinical setting for IL8-or CXCR1/2-neutralizing antibodies.